Switch theme
Sign up to access all valuation multiples
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
2012
55K+
LTM Revenue $56.8B
LTM EBITDA $24.8B
$418B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AbbVie has a last 12-month revenue of $56.8B and a last 12-month EBITDA of $24.8B.
In the most recent fiscal year, AbbVie achieved revenue of $56.3B and an EBITDA of $14.9B.
AbbVie expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AbbVie valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $58.1B | $54.3B | $56.3B | $56.8B | XXX |
| Gross Profit | $40.6B | $33.9B | $39.4B | XXX | XXX |
| Gross Margin | 70% | 62% | 70% | XXX | XXX |
| EBITDA | $24.2B | $17.2B | $14.9B | $24.8B | XXX |
| EBITDA Margin | 42% | 32% | 26% | 44% | XXX |
| Net Profit | $11.8B | $4.9B | $4.3B | XXX | XXX |
| Net Margin | 20% | 9% | 8% | XXX | XXX |
| Net Debt | $54.1B | $46.6B | $61.6B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, AbbVie's stock price is $202.
AbbVie has current market cap of $357B, and EV of $418B.
See AbbVie trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $418B | $357B | XXX | XXX | XXX | XXX | $10.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, AbbVie has market cap of $357B and EV of $418B.
AbbVie's trades at 7.4x LTM EV/Revenue multiple, and 16.9x LTM EBITDA.
Analysts estimate AbbVie's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for AbbVie and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $418B | XXX | XXX | XXX |
| EV/Revenue | 7.4x | XXX | XXX | XXX |
| EV/EBITDA | 28.1x | XXX | XXX | XXX |
| P/E | 83.4x | XXX | XXX | XXX |
| P/E/Growth | 0.6x | XXX | XXX | XXX |
| EV/FCF | 23.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAbbVie's NTM/LTM revenue growth is 6%
AbbVie's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, AbbVie's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate AbbVie's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for AbbVie and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 49% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AbbVie acquired XXX companies to date.
Last acquisition by AbbVie was XXXXXXXX, XXXXX XXXXX XXXXXX . AbbVie acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was AbbVie founded? | AbbVie was founded in 2012. |
| Where is AbbVie headquartered? | AbbVie is headquartered in United States of America. |
| How many employees does AbbVie have? | As of today, AbbVie has 55K+ employees. |
| Who is the CEO of AbbVie? | AbbVie's CEO is Mr. Robert A. Michael. |
| Is AbbVie publicy listed? | Yes, AbbVie is a public company listed on NYS. |
| What is the stock symbol of AbbVie? | AbbVie trades under ABBV ticker. |
| When did AbbVie go public? | AbbVie went public in 2012. |
| Who are competitors of AbbVie? | Similar companies to AbbVie include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AbbVie? | AbbVie's current market cap is $357B |
| What is the current revenue of AbbVie? | AbbVie's last 12-month revenue is $56.8B. |
| What is the current EBITDA of AbbVie? | AbbVie's last 12-month EBITDA is $24.8B. |
| What is the current EV/Revenue multiple of AbbVie? | Current revenue multiple of AbbVie is 7.4x. |
| What is the current EV/EBITDA multiple of AbbVie? | Current EBITDA multiple of AbbVie is 16.9x. |
| What is the current revenue growth of AbbVie? | AbbVie revenue growth between 2023 and 2024 was 4%. |
| Is AbbVie profitable? | Yes, AbbVie is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
